Abstract:Melatonin, an endogenous neurohormone produced by the pineal gland, has received increased interest due to its potential anti-cancer properties. Apart from its well-known role in the sleep–wake cycle, extensive scientific evidence has shown its role in various physiological and pathological processes, such as inflammation. Additionally, melatonin has demonstrated promising potential as an anti-cancer agent as its function includes inhibition of tumorigenesis, induction of apoptosis, and regulation of anti-tumor immune response. Although a precise pathophysiological mechanism is yet to be established, several pathways related to the regulation of cell cycle progression, DNA repair mechanisms, and antioxidant activity have been implicated in the anti-neoplastic potential of melatonin. In the current manuscript, we focus on the potential anti-cancer properties of melatonin and its use in treating and managing pediatric osteosarcoma. This aggressive bone tumor primarily affects children and adolescents and is treated mainly by surgical and radio-oncological interventions, which has improved survival rates among affected individuals. Significant disadvantages to these interventions include disease recurrence, therapy-related toxicity, and severe/debilitating side effects that the patients have to endure, significantly affecting their quality of life. Melatonin has therapeutic effects when used for treating osteosarcoma, attributed to its ability to halt cancer cell proliferation and trigger apoptotic cell death, thereby enhancing chemotherapeutic efficacy. Furthermore, the antioxidative function of melatonin alleviates harmful side effects of chemotherapy-induced oxidative damage, aiding in decreasing therapeutic toxicities. The review concisely explains the many mechanisms by which melatonin targets osteosarcoma, as evidenced by significant results from several in vitro and animal models. Nevertheless, if further explored, human trials remain a challenge that could shed light and support its utility as an adjunctive therapeutic modality for treating osteosarcoma.

3D-printing magnesium–polycaprolactone loaded with melatonin inhibits the development of osteosarcoma by regulating cell-in-cell structures

Multifunctional magnesium incorporated scaffolds by 3D-Printing for comprehensive postsurgical management of osteosarcoma

Melatonin Inhibits Osteosarcoma Stem Cells by Suppressing SOX9-mediated Signaling.

Time‐sequential and Multi‐functional 3d Printed Mgo2/PLGA Scaffold Developed as A Novel Biodegradable and Bioactive Bone Substitute for Challenging Postsurgical Osteosarcoma Treatment

Biofunctional Magnesium-Coated Ti6Al4V Scaffolds Promote Autophagy-Dependent Apoptosis in Osteosarcoma by Activating the AMPK/mTOR/ULK1 Signaling Pathway

Melatonin Inhibits the Proliferation of Human Osteosarcoma Cell Line MG-63

3D-Printed Magnesium Peroxide-Incorporated Scaffolds with Sustained Oxygen Release and Enhanced Photothermal Performance for Osteosarcoma Multimodal Treatments

Melatonin Inhibits the Proliferation of Human MG-63 Osteosarcoma Cells via Downregulation of Cyclins and CDKs

Anticancer effects of melatonin via regulating lncRNA JPX-Wnt/β-catenin signalling pathway in human osteosarcoma cells

Biodegradable Magnesium Implants: a Potential Scaffold for Bone Tumor Patients

Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway

Unveiling the Protective Role of Melatonin in Osteosarcoma: Current Knowledge and Limitations

Multifunctional 3D-printed scaffolds eradiate orthotopic osteosarcoma and promote osteogenesis via microwave thermo-chemotherapy combined with immunotherapy

MgSiO3 Fiber Membrane Scaffold with Triggered Drug Delivery for Osteosarcoma Synergetic Therapy and Bone Regeneration

Nanoengineered 3D-printing scaffolds prepared by metal-coordination self-assembly for hyperthermia-catalytic osteosarcoma therapy and bone regeneration

A novel poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV)-PEG-melatonin composite scaffold enhances for inhibiting bone tumor recurrence and enhancing bone regeneration

SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells.

Ferric Oxide Nanosheet-Engineered Mg Alloy for Synergetic Osteosarcoma Photothermal/chemodynamic Therapy

Conductive Material Gel@Ti3C2/MT Regulates the PI3K/AKT/HIF-1α/TIMP1 Pathway Affecting MT1 for Inhibiting Osteosarcoma

Melatonin Suppresses Epithelial‑to‑mesenchymal Transition in the MG‑63 Cell Line.

3D-printed MgO nanoparticle loaded polycaprolactone β-tricalcium phosphate composite scaffold for bone tissue engineering applications: In-vitro and in-vivo evaluation